Jade Biosciences Inc Dossier - Source-backed chat

Jade Biosciences Inc

JBIONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.31

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $13.77Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $875.7M

Enterprise Value $768.5M

Shares Outstanding 63.6M diluted

Next Earnings Date30 Jun 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Jade Biosciences (Nasdaq: JBIO) is a clinical-stage biotechnology company developing potentially best-in-class monoclonal antibodies for autoimmune diseases. The company's lead asset, JADE101, targets the cytokine APRIL for the treatment of IgA nephropathy (IgAN). Recent Phase 1 healthy volunteer data demonstrated a highly competitive profile, showing a ~70% IgA reduction sustained at 12 weeks after a single dose, supporting a convenient every-12-week dosing regimen. Backed by a strong balance sheet with a cash runway extending into 1H 2028 following a $172.5 million public offering in June 2026, Jade is well-positioned to advance its pipeline through multiple clinical catalysts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$40.00

Mean target$50.13

High · most bullish analyst$77.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$40.0015%

JADE101 fails to replicate its Phase 1 IgA reduction durability in IgAN patients, or safety concerns emerge during the Phase 2 JUNIPER trial. JADE201 clinical development is delayed, or competitive pressures from approved therapies (e.g., Novartis's iptacopan) limit the market opportunity, leading to a significant downward re-rating.

Base CaseCentral scenario

$50.1360%

Matches the consensus mean

JADE101 achieves its target profile in the Phase 2 JUNIPER trial, showing competitive IgA reductions and a favorable safety profile that supports progression to a Phase 3 registrational trial in 1H 2027. JADE201 advances smoothly through Phase 1. The company's cash runway remains sufficient to reach these key 2027 milestones without immediate dilutive financing.

Bull CaseUpside scenario

$77.0025%

JADE101 demonstrates superior clinical efficacy in Phase 2 trials with rapid, deep, and durable IgA and proteinuria reductions, establishing it as the clear best-in-class anti-APRIL therapy. JADE201 successfully demonstrates robust B-cell depletion in rheumatoid arthritis. Strong clinical data triggers lucrative pharmaceutical partnerships or an acquisition at a premium valuation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated lead asset (JADE101) with potential best-in-class every-12-week subcutaneous dosing profile.
Strong financial position with cash runway extending into the first half of 2028 following the June 2026 capital raise.
Robust pipeline including JADE201 (anti-BAFF-R) and JADE301, licensed from the validated Paragon Therapeutics discovery engine.

Key Investment Risks

Clinical development risk, as the company is pre-revenue and entirely dependent on the success of unapproved candidates.
Intense competition in the IgA nephropathy space from established pharmaceutical players and approved therapies.
Potential for future equity dilution to fund late-stage clinical trials beyond 2028.

Thesis Invalidation Triggers

Failure of JADE101 to show significant proteinuria reduction or acceptable safety in the Phase 2 JUNIPER trial.
Unexpected clinical holds or regulatory delays imposed by the FDA on the JADE101 or JADE201 programs.
Severe cash burn acceleration that shortens the projected runway significantly below the 1H 2028 target.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.